Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07697274
EARLY_PHASE1

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Sponsor: Medical University of South Carolina

View on ClinicalTrials.gov

Summary

Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.

Official title: Digital Intradermal Hyaluronidase for Sclerodactyly in Systemic Sclerosis

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-09-01

Completion Date

2027-11

Last Updated

2026-07-13

Healthy Volunteers

No

Interventions

DRUG

Hyaluronidase (Hylenex)

Patients will receive monthly injections of hyaluronidase into 1 finger on each hand over a 28 week treatment period.

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States